nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Home nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

/ Publications

Share the Post

About the Author

Related Posts

Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Read More
Richard Maroun, JD

Comments

Comments are closed.